Beboxia 50AM Tablet
Manufacturer
Wings Biotech Ltd
Salt Composition
Amlodipine (5mg) + Metoprolol Succinate (0mg)
Key Information
Short Description
Beboxia 50AM Tablet is a combination of two medicines that help control high blood pressure and heart rate, and is used for heart-related chest pain, abnormal heart rhythms, and chronic heart failure.
Dosage Form
Tablet
Introduction
Beboxia 50AM Tablet is a combination of two medicines that help control high blood pressure and heart rate. It is used for heart-related chest pain (angina), abnormal heart rhythms, and chronic (long-term) heart failure. It is also used to treat high blood pressure.
Directions for Use
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Beboxia 50AM Tablet may be taken with or without food but it is better to take it at a fixed time.
Safety Information
Side Effects
No common side effects listed.
Alcohol Warning
It is unsafe to consume alcohol with Beboxia 50AM Tablet.
Breastfeeding Warning
Beboxia 50AM Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Pregnancy Warning
Beboxia 50AM Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
How it works
Beboxia 50AM Tablet is a combination of two medicines that work together to control high blood pressure and heart rate.
Quick Tips
It may cause dizziness. Get up slowly when rising from a sitting or lying position. Do not stop taking the medication suddenly without talking to your doctor as it can cause sudden increase in your blood pressure. Let your doctor know if you are pregnant or planning for pregnancy.
Related Medicines
Metolar Am-50 Tablet
Best-Beta-AM 50 Tablet
Renowell AM 5mg/50mg Tablet
Cure BP M 5mg/50mg Tablet
Eurobeta-AM Tablet
Zumet A 5mg/50mg Tablet
Acord M 5mg/50mg Tablet
Metwon AM 50 Tablet
Bitmet AM 5mg/50mg Tablet
Amlomet 5mg/50mg Tablet
Frequently asked questions
Can I stop taking Beboxia 50AM Tablet if I feel well?
No, it is essential to continue taking Beboxia 50AM Tablet as advised by your doctor, even if you feel well. Sudden discontinuation of the medication may lead to serious complications, including heart attack and stroke. Consult your doctor for personalized guidance on medication use.
What are the instructions for the storage and disposal of Beboxia 50AM Tablet?
To ensure the safety and efficacy of Beboxia 50AM Tablet, store it in its original packaging, tightly closed, according to the instructions provided on the pack or label. Dispose of any unused medication properly, and ensure it is not accessible to pets, children, or other individuals.
Can the use of Beboxia 50AM Tablet cause headache?
Yes, headaches are a common side effect of Beboxia 50AM Tablet, typically occurring during the initial stages of treatment. In most cases, headaches resolve within the first week of treatment. If you experience frequent or persistent headaches, consult your doctor for guidance and potential adjustments to your treatment plan.
What are the contraindications associated with the use of Beboxia 50AM Tablet?
Beboxia 50AM Tablet is contraindicated in patients with a known allergy to any of its active or inactive ingredients. Additionally, it is not recommended for patients with a history of asthma or lung disease. Inform your doctor about your medical history and current medications to minimize the risk of adverse reactions.
Can I feel dizzy after taking Beboxia 50AM Tablet?
Yes, Beboxia 50AM Tablet may cause dizziness, particularly when rising from a lying or sitting position. To reduce the likelihood of dizziness or fainting, rise slowly and carefully when changing positions. If you experience persistent or severe dizziness, consult your doctor for guidance and potential adjustments to your treatment plan.
